Argenx Patient Finder Suitability Analysis

Pitch Hook: "80% of ocular myasthenia gravis patients progress to generalized disease within 2 years, yet 15-20% remain undiagnosed or misattributed to 'eye strain,' 'dry eyes,' or 'normal aging' for months to years before neurology referral. Ocular MG presents with the most specific symptom pattern in Argenx's entire portfolio—fluctuating ptosis (drooping eyelids) and diplopia (double vision) worsening with reading, driving, or screen time and improving with rest or cool temperature—a combination that Ada's clinical assessment can identify with near-perfect precision. With VYVGART's ocular MG launch anticipated in 2027 and each early-diagnosed patient representing $1.07 million in lifetime revenue (2-3 years treatment to prevent progression), 8-12% of first-year sales ($43,000) to Ada, and Argenx's explicit strategy to 'treat patients earlier in their disease course to prevent progression to generalized disease,' Patient Finder offers the pre-launch patient identification infrastructure Argenx needs to capture 750-1,000 new ocular MG patients annually before they progress."

Pitch Hook: "27% of generalized myasthenia gravis patients experience diagnostic delays exceeding one year, with two-thirds initially misdiagnosed as chronic fatigue, depression, or hysteria. These patients present with a highly distinct symptom pattern—fluctuating ptosis (drooping eyelids), diplopia (double vision), dysphagia, and limb weakness worsening with activity but improving with rest—that Ada's clinical assessment is uniquely positioned to surface before the diagnostic odyssey extends beyond 850 days. With each correctly identified gMG patient representing $829,000 in lifetime VYVGART revenue and 8-12% of first-year sales ($33,000) to Ada, Patient Finder can unlock 900-1,700 undiagnosed patients annually in the US alone, directly supporting Argenx's Vision 2030 goal of treating 50,000 patients globally and accelerating the 2,000 new patient starts per year needed to reach that target."

Pitch Hook: "68% of CIDP patients are initially misdiagnosed—most commonly as radiculopathy, GBS, or diabetic neuropathy—with electrophysiological errors contributing to 85% of pre-referral misdiagnoses and treatment delays averaging 21 months in affected cases. Ada's symptom assessment can identify the CIDP pattern—progressive symmetric weakness with both proximal and distal involvement, areflexia, numbness, and unexplained falls—that differentiates CIDP from the single-nerve radiculopathies and stable diabetic neuropathies neurologists see daily. With each CIDP patient representing $2.35 million in lifetime VYVGART revenue (5+ years treatment) and 8-12% of first-year sales ($47,000) to Ada, Patient Finder can capture 550-750 undiagnosed patients annually in the US from a pool of 78,000 prevalent cases (newly revised 2023 epidemiology showing 3-4× higher prevalence than prior estimates)."

Pitch Hook: "Idiopathic inflammatory myopathies are rare, severe autoimmune muscle diseases often misattributed to fibromyalgia or polymyalgia rheumatica for 6-12 months before rheumatology referral and muscle biopsy. Dermatomyositis—the most recognizable subtype—presents with a pathognomonic symptom pattern: heliotrope rash (purple eyelid discoloration), Gottron's papules (scaly red patches over knuckles), photosensitivity, and proximal muscle weakness (difficulty rising from chair, climbing stairs). Ada's symptom assessment can surface DM patients earlier by differentiating them from fibromyalgia based on objective weakness + characteristic rash rather than diffuse pain alone. With each IIM patient representing $2.1 million in lifetime VYVGART revenue and 8-12% of first-year sales ($47,000) to Ada, Patient Finder can accelerate diagnosis and referral for 150-220 undiagnosed patients annually."

Pitch Hook: "67% of multifocal motor neuropathy patients experience diagnostic delays exceeding one year, with 70% initially misdiagnosed as radiculopathy, peripheral neuropathy, or early ALS before EMG conduction block studies confirm MMN. Patients present with a distinctive asymmetric pattern—foot drop in one leg combined with wrist drop or hand weakness in the opposite arm, cramping, and fasciculations—in a non-dermatomal distribution that Ada's symptom assessment can differentiate from the single-nerve radiculopathies and symmetric polyneuropathies neurologists encounter daily. With each MMN patient representing $756,000 in lifetime empasiprubart revenue (5+ years of IVIg-displacing therapy) and 8-12% of first-year sales ($15,000) to Ada, Patient Finder can unlock 25-50 undiagnosed patients annually from a pool of 3,350 prevalent US cases."